Posts tagged Pharma
Drug Pricing: An Industry Perspective

Since the advent of biosynthetic insulin in the 1980s, tremendous advances in science have given rise to biologic medicines that have dramatically improved both options and outcomes for patients. Yet, as the focus of the healthcare industry has shifted to cost containment and comparative value, the pricing of these novel medicines has come under widespread scrutiny. Today, Pulse catches up with the Chief Strategy Officer of Biogen, Dr. Adam Koppel, to gather the perspective of an industry veteran.

Read More